Compare Ascendis Pharma A/S (ASND) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Simon Property Group Inc — how do they compare? Ascendis Pharma A/S trades at $263 (market cap $17.74B), while Simon Property Group Inc trades at $219.06 (market cap $70.94B). The key difference: Simon Property Group Inc is far larger — about 4× Ascendis Pharma A/S's market cap, and Simon Property Group Inc pays a 4.02% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SPG | |
|---|---|---|
Market Cap | $17.74B | $70.94B |
Sector | Health | Real Estate |
52-Week High | $277.18 | $227.56 |
52-Week Low | $163.32 | $159.93 |
Enterprise Value | $18.11B | $99.42B |
Dividend Yield | — | 4.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Simon Property Group (SPG) trades at $218.77, down 0.43% on the day, with a bullish technical signal from moving averages. The REIT shows strong profitability with a 70.59% net income margin and has beaten earnings estimates in three consecutive quarters. Recent news highlights robust Q1 2026 results and a dividend payout of $2.25 for H1-26.
Outlook remains positive due to strong leasing and redevelopment, but risks include high debt levels and e-commerce competition. Analyst consensus is mixed with a $214.40 price target, slightly below current levels, suggesting cautious optimism amid solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
